Biopharma may see a happier year ahead in 2026 than in recent years, according to analysts at William Blair. For one thing, the industry’s top stocks have recovered from lows that stretched into last ...

When President Donald Trump declared in May that he wanted drug companies to voluntarily cut their prices, few pharmaceutical executives wanted to go first. Now, no one wants to be last – and risk the ...

We recently published 12 Stocks on Jim Cramer’s Radar. Pfizer Inc. (NYSE:PFE) is one of the stocks on Jim Cramer’s radar.

Pfizer is targeting supply chain emissions and engaging suppliers to build a climate-resilient value chain for the future ...

Eli Lilly’s retatrutide exceeds expectations in Phase III, capping off a sparkling 2025 for the obesity titan; an internal ...

Find insight on Corcept Therapeutics, vaccine skepticism and more in the latest Market Talks covering the health care sector.

Pfizer revised its revenue expectations for 2025 and detailed its outlook for 2026. Pfizer said revenue should come in at the lower end of its guidance for this year, while it expects less revenue in ...

Pfizer signaled Tuesday it expects a challenging 2026 as it invests in new products to offset declines in Covid-19 revenues ...

I agree to the Terms of Use , Privacy Notice and Cookie Notice. I agree to the Terms of Use , Privacy Notice and Cookie ...

Pfizer Inc. forecast little to no sales growth next year as the drugmaker undertakes an effort to refresh its pipeline of hit ...